ISSN: 2167-065X

Klinische Pharmakologie und Biopharmazeutik

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Gut Restricted Therapeutic Approaches to Inflammatory Bowel Disease

Pranab Maiti* and Rajiv Sharma

Inflammatory Bowel Disease (IBD), consisting of Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a chronic intestinal disorder arises due to the damaged intestinal epithelium tissue which most often leads to relapsing. Major treatment options range from dietary intervention at an early stage of the disease, to the use of steroids or anti-inflammatory drugs for the severe most conditions. However, the side effects and associated comorbidities which bring disease recurrences points towards the unmet needs of the existing treatment options which are limited to their non-holistic mechanistic functionality. Among them, many drugs work specifically by acting locally on the gut tissue, in other words at the site of the disease; both to exert maximal efficacy as well as to avoid undesired side effects. Here we have reviewed the recent interests in the gut restricted therapeutic approaches for new IBD therapies.